There is no denying the fact that anyone who raises a voice about the wrongdoings in the pharmaceutical industry in India is treated as a traitor and put on series of trouble through never ending court trials and personal harm.
 |
| Photo (https://unsplash.com/photos/5tyMgag0wRo) |
Katherine Eiban's book, "Bottle of Lies", which sheds light on developments in the generic drug industry, was recently published. The book has received a great response from readers and critics, especially those who are keeping an eye on the developments in the pharmaceutical industry in India. This kind of critique, as it has been criticized, does not appear in our media with even the slightest exception. On the contrary, in such a process, instead of giving open information, the author is personally attacked, his journalistic ethics are questioned.
A recent example of this trend is the biased mentality of Katherine Iban, the author of the book . On Twitter , too, many are sharply critical.
The attacks on Iban are either a response to the criticism leveled at him by the Indian pharmaceutical industry. An important response to such a response is the threat of filing a defamation suit. In fact, all this is treasonous and a conspiracy against the Indian pharmaceutical industry, with immature perceptions and mentality threatening to file a defamation suit. In this article we will talk about this point in detail with more examples.
Dr. who edits the monthly rating list of medical experts. Chander Gulati wrote that Deanxit was banned in Canada, where it was manufactured, but that it was widely available in India .However, because of this, Dr. Gulati was charged in 2012 with defamation for defamation. Since then, the question of how safe Deanxit has been has been debated. According to a report by the Parliamentary Committee on Control of Drug Standards (CDSCO), the Ministry of Health has banned the drug twice. However, the Karnataka High Court has twice overturned the ban, saying it was suspicious or unfounded. Last year, I myself filed a petition in the Delhi High Court seeking a ban on the drug and its expulsion from the Indian market. Importantly, it is hoped that the Drug Testing Advisory Board (DTAB) will make a recommendation soon.
In 2013, it was revealed that Ranbaxy had violated seven US drug standards by supplying substandard drugs to the US market. Some hospitals and drug dealers in India have since demanded that the government disclose the drugs Ranbaxy supplies and sells in India and clarify whether we should buy them or not. One thing that is more obvious and like an open secret is that the regulatory framework in India regarding pharmaceuticals is so vague that it leads to two mutually different levels of pharmaceutical manufacturing.
Some pharmaceutical companies in India produce medicines of exportable quality. For this they adopt the best practices (CGMP) currently in force for pharmaceuticals. In contrast, Schedule M of the law for the manufacture of drugs used in India does not appear to have such stringent standards. When it came to hearing about the quality of medicines exported from India to the United States, the leaders of India's pharmaceutical industry said that they were doing their best for the benefit of the patients. The incident was said to be a conspiracy against India's pharmaceutical industry by the then Government of India and a group of Indian companies that dominated the pharmaceutical industry.
In 2014, a group of North American academic researchers published a research report on how pharmaceutical companies in India sell the same drug in different countries, and how the quality of the drug varies from country to country. Among them was Amir Attaran of the University of Ottawa. At the time, the Indian government had threatened to sue the researchers, saying they had defamed India's pharmaceutical industry. At the same time, lawyer Gautam Bhatia had made it clear that even if India had taken such action, it would not have stood the test of law.
There was something wrong with JVK Bio, a pharmaceutical company. In 2015, a man risked his life to expose these things. However, at that time, the world of systems and pharmaceutical industry provided the story of that person's love story to the media. Of course, spreading this love story did not do much good.
In 2016, I had moved the Supreme Court through a public interest litigation. So, I questioned the quality of Indian medicines in the Indian courts, so I was treated as a 'traitor' by the Director General of Drugs of India. The court had also rejected my plea on the ground that my claims on the petition were subject to academic study and that India had made bio-equivalence and sustainability testing mandatory. In fact, I had raised both these issues in my public interest litigation. I then filed a second PIL in the Delhi High Court. Following this petition, the two drugs that were questioned in the original petition I filed in the Supreme Court were either banned or banned by the respective companies. As I only filed a petition on these developments, We can certainly guess that a company should shut down the drugs that make them profitable on its own. In fact, I honestly want to mention that at the time, I was thinking only of the interests of patients in India.
I am sure that anyone else who has spoken out about the wrongdoings in the pharmaceutical industry in India would have been called traitors and defamatory by the pharmaceutical industry and the hegemonic groups in the industry. After all, journalists and editors need to understand that the problems of the pharmaceutical world will not be left behind by any personal attack, or by the threat of defamation claims. We have already seen many cases of voices being suppressed in this way. All I can say is that this will continue to happen because that is what is expected.
It is worth noting that the trick of diverting attention from the main thing has added another dimension. That is, when an issue cannot be countered, the benefactors of this industry try to draw your attention to what the Indian pharmaceutical industry has given to the world.
It is said that generic drugs can cover the cost of healthcare, making it affordable. For this reason, it is often said that Indian pharmaceutical companies played a vital role in making life-saving drugs available to the general public at a time when HIV infection was on the rise. However, in discussing all this, the biggest problem we face is ignored, and that is, what exactly is the quality of the medicine we are supplying?
Another way to divert your attention is to point out, or talk about, the mistakes of other big pharmaceutical companies (there's a lot to talk about, including unlabelled drugs, financial scandals, etc.) and do whatever it takes. So there's not much going wrong.
None of this is really related to the point we are discussing. Going beyond that, this benevolent congregation sings sweet songs in many respects of the Indian pharmaceutical industry. One of the most widely used issues is the Indian pharmaceutical industry's role in making medicines available to patients around the world at affordable prices. In fact, what should we learn from this? So it is that if you deliberately give an ignorant patient the best quality and ineffective medicine in terms of treatment, then in fact no one gets any special benefit.
In a country like India, where the system for studying the long-term effects of substandard drugs is as scattered as possible. Now, in a country where two different types of pharmaceuticals are being developed, it is important to know who is responsible for disinfection / infertility, hygiene, and registration of medicines that are at least life-saving. Leads.
The regulators of this industry and the hegemonic groups and the advocates of this industry do not even realize that the tricks they have used to defend themselves to this day were exposed to the public in May 2013. However, there is no reason for the sudden decline of the industry today to be exposed. Once upon a time, the pharmaceutical industry, like the IT sector, was known as the rising sun. This is because the region has given India a large foreign exchange. But today, the same industry is in decline.
When the performance of any industry deteriorates, it affects not only the financial investors but also the lives of millions of young people. Because they would have seen this sector as a lucrative area for employment. The paradox of all this is that in the last five years, the industry has not been able to change the future of the industry by using the same tactics that it has used to defend itself. Even in such a situation, I am really surprised that he used the same approach again and again to face the problems and allegations.
All those who want the Indian pharmaceutical industry to regain its lost glory as a "global drug hub" should discuss the facts without discussing any controversy. Because at some point on an emotional level, disagreements can be useful. However, the fact that only 3% of the NSQs in our supply of drugs are standardised, whether this claim is true or not, will depend on the facts and circumstances.
Post a Comment